trial
as of 2026-07-01A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia
NCTId NCT05693935
at a glance
Phase 3 · Completed
Enrollment 675 (actual)
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc.
Primary completion 2024-03-19
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
675 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2023-01-24
Primary completion
2024-03-19
Eligibility
ALL · 18 Years · 64 Years
Interventions & indications
Drugs
Indications
Sponsors
Teva Branded Pharmaceutical Products R&D, Inc.Lead Sponsor
Investigators
1
Teva Medical Expert, MDStudy Director
Sites
82 total
Bentonville, United StatesLittle Rock, United StatesRogers, United StatesAnaheim, United StatesBellflower, United StatesGarden Grove, United StatesLa Habra, United StatesLemon Grove, United StatesLong Beach, United StatesLos Angeles, United StatesLos Angeles, United StatesOrange, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
675
Phase
PHASE3
Primary Completion Date
2024-03-19
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
indication
indication
indication
investigator
person